Full-year results and trial data dominated healthcare news, with a diagnostics company's shift toward partnered distribution taking centre stage alongside a biotech fundraise, a major pharma earnings update and fresh trial safety data from a medical device developer. The common thread was commercial validation, through distribution deals, oversubscribed raises, growth drivers and tolerability data, rather than share-price drama.
Renalytix lands Quest Diagnostics distribution deal after flat year
Renalytix (AIM:RENX) reported flat revenue of $3.0 million for the twelve months to 30 June, unchanged from the prior year, as the AIM-listed kidney disease diagnostics company pivoted away from direct sales toward a partnered distribution model that has since culminated in a national agreement with Quest Diagnostics. The shares fell 5.38% to 5.63p as the market digested a results set that showed the underlying commercial transition still working through the numbers. Renalytix's KidneyIntelX platform applies artificial intelligence to flag early-stage risk in chronic kidney disease, and its kidneyintelX.dkd test carries both FDA approval and Medicare reimbursement for diabetic kidney disease, a distinction the company says no comparable prognostic test holds.
Commercial test revenues slipped to $2.2 million from $2.7 million a year earlier, a decline Renalytix pinned on a smaller sales team and the lag in electronic medical record integrations as it stepped back from direct selling. Life sciences revenue, by contrast, rose to $0.8 million from $0.3 million on higher research and clinical study-related testing. Losses narrowed across the board: underlying EBITDA loss improved to $12.1 million from $14.0 million, operating loss fell to $14.0 million from $17.2 million on a $3.2 million cut in administrative costs to $15.2 million, and the pre-tax loss shrank to $14.7 million from $21.8 million. Cash and cash equivalents stood at just $1.4 million at period end, down from $3.6 million a year earlier, a balance that underscores why the Quest tie-up matters so much to the company's near-term prospects.
Since the period closed, Renalytix has signed a multi-year national distribution agreement with Quest Diagnostics, announced in September, giving clinicians access to order kidneyintelX.dkd through Quest's connectivity network spanning all 50 US states, roughly 2,000 patient service centres and 6,000 phlebotomists. The company said the deal removes the need for bespoke IT integration with individual health systems and expects physician ordering to begin in the first quarter of 2027, targeting roughly 25,000 tests ordered that year.
The Quest agreement effectively outsources the distribution burden that drained Renalytix's direct sales economics over the past year, trading near-term revenue softness for what the company is betting will be a scalable ordering channel without the capital intensity of building out its own sales force. With cash reserves down to $1.4 million, the success of that channel, and the pace at which the 2027 ordering target materialises, will determine whether the narrower losses reported this year mark a genuine inflection or merely a pause before the next funding question.
Sareum upsizes fundraise as retail offer closes early
Sareum Holdings (AIM:SAR) raised around £3.34 million in total after its retail offer was oversubscribed and closed early, prompting the clinical-stage biotech to upsize the raise to absorb excess demand. Shares rose 4.62% to 17.0p on the news. The retail offer, run through the Winterflood Retail Access Platform, added approximately £150,000 to the previously announced subscription, with Sareum issuing 1.07 million new shares at the issue price to retail investors.
Combined with the 22.81 million shares issued under the subscription, announced on 26 October and priced at 14p each, a discount to the 27.5p closing price before trading was paused on 7 October, the two raises together produced gross proceeds of roughly £3.34 million. Sareum develops oral kinase inhibitors for autoimmune disease and cancer, with lead candidate SDC-1801 being advanced toward Phase 2 as a treatment for psoriasis.
The strong retail demand and early closure signal investor appetite for the SDC-1801 programme ahead of its Phase 2 push, giving Sareum a funding runway at a moment when the stock had been suspended just weeks earlier pending the fundraise terms. The oversubscription also suggests the 14p discount was pitched conservatively enough to draw buyers back once trading resumed.
GSK lifts quarterly turnover on Specialty Medicines growth
GSK (LSE:GSK) reported third-quarter turnover of £8.9 billion, up 5% at constant exchange rates, as a 15% jump in Specialty Medicines sales offset a decline in Vaccines and flat General Medicines revenue. The FTSE 100 constituent's shares fell 5.15% to 1824.5p despite core operating profit rising 5% to £3.1 billion and core earnings per share increasing 1% to 54.6p; total operating profit fell 16% and total EPS dropped 21% to 38.5p after £328 million in major restructuring charges tied to its Accelerate Growth programme.
Specialty Medicines sales reached £3.9 billion, led by HIV revenue of £2.1 billion, up 10%, with long-acting injectables Cabenuva and Apretude driving most of the growth. Respiratory, Immunology & Inflammation sales rose 21% to £1.1 billion and Oncology grew 23% to £622 million, with Jemperli, Ojjaara/Omjjara and Blenrep all posting gains. Vaccines turnover fell 2% to £2.6 billion, with Shingrix down 5% to £780 million on weaker demand. "GSK has delivered another strong quarter, with our key growth drivers and new launches performing well. We remain focused on operational delivery, execution and accelerating R&D," said Luke Miels, chief executive officer of GSK.
The divergence between core and total profit figures highlights the near-term cost of GSK's restructuring drive even as its newer growth engines, HIV long-acting therapies, respiratory and oncology, demonstrate they can offset vaccine softness. The scale of the restructuring charge suggests management is prepared to absorb short-term earnings pain to reposition the portfolio around higher-growth specialty categories, a trade-off the market appeared to price cautiously despite the headline sales beat.
Ondine says LANTERN treatment was well tolerated by patients
Ondine Biomedical (AIM:OBI) reported that just 0.31% of patients in its Phase 3 LANTERN trial experienced a treatment-related adverse event, with all eight cases described as mild, sending shares up 2.37% to 9.725p. The AIM-listed medical device company, which develops light-activated antimicrobial therapies to prevent hospital-acquired infections, presented the safety and tolerability results alongside research partner HCA Healthcare Research Institute at IDWeek 2026 in Washington, D.C.
The safety analysis covered 2,543 participants who received Ondine's Steriwave nasal photodisinfection between 27 December 2024 and 27 April, drawn from the trial's full 5,188-patient population across 18 hospitals in the US and Canada. Among those treated, eight experienced a treatment-related adverse event, temporary nasal soreness, mild burning or transient bleeding, with none serious. Patient acceptance was high, with 2,249 of 2,310 respondents rating the treatment "very bearable" or "bearable". "These safety results from the LANTERN trial demonstrate that preoperative nasal photodisinfection was exceptionally well tolerated by patients in a real-world clinical setting," said Carolyn Cross, chief executive of Ondine Biomedical.
Clean tolerability data at this scale strengthens Ondine's case for Steriwave's eventual adoption as a routine preoperative step rather than a niche intervention, addressing one of the key hurdles, patient and clinician comfort, standing between trial results and hospital formulary decisions. With the full 5,188-patient LANTERN dataset still to be reported, this tranche of safety findings gives the company a positive marker to build on as it approaches the trial's broader efficacy conclusions.